| Title |
Pharmacokinetic considerations on the repurposing of ivermectin for treatment of COVID‐19
|
|---|---|
| Published in |
British Journal of Clinical Pharmacology, July 2020
|
| DOI | 10.1111/bcp.14476 |
| Pubmed ID | |
| Authors |
Login to access the Attention Digest and the Sentiment Analysis related to this output.
An error occurred while generating this chart. Please try again later.
No score history available for this output yet. Please try again later.
X Demographics
The data shown below were collected from the profiles of 132 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Colombia | 21 | 16% |
| United States | 13 | 10% |
| United Kingdom | 5 | 4% |
| Netherlands | 4 | 3% |
| Australia | 4 | 3% |
| Italy | 2 | 2% |
| Germany | 2 | 2% |
| Belgium | 2 | 2% |
| India | 2 | 2% |
| Other | 17 | 13% |
| Unknown | 60 | 45% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 113 | 86% |
| Scientists | 11 | 8% |
| Practitioners (doctors, other healthcare professionals) | 8 | 6% |
Mendeley demographics
The data shown below were compiled from readership statistics for 149 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 149 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Bachelor | 25 | 17% |
| Researcher | 10 | 7% |
| Other | 9 | 6% |
| Student > Ph. D. Student | 9 | 6% |
| Student > Master | 8 | 5% |
| Other | 27 | 18% |
| Unknown | 61 | 41% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 23 | 15% |
| Pharmacology, Toxicology and Pharmaceutical Science | 19 | 13% |
| Biochemistry, Genetics and Molecular Biology | 9 | 6% |
| Agricultural and Biological Sciences | 6 | 4% |
| Chemistry | 6 | 4% |
| Other | 22 | 15% |
| Unknown | 64 | 43% |
Attention Score in Context
This research output has an Altmetric Attention Score of 765. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 23 July 2026.
All research outputs
#32,343
of 34,622,316 outputs
Outputs from British Journal of Clinical Pharmacology
#3
of 7,032 outputs
Outputs of similar age
#1,115
of 441,185 outputs
Outputs of similar age from British Journal of Clinical Pharmacology
#1
of 127 outputs
Altmetric has tracked 34,622,316 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 99th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 7,032 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 11.4. This one has done particularly well, scoring higher than 99% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 441,185 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 99% of its contemporaries.
We're also able to compare this research output to 127 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 99% of its contemporaries.